MedPath

Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com
Introduction

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

2.1k

Active:124
Completed:1631

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:478
Phase 2:409
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1728 trials with phase data)• Click on a phase to view related trials

Phase 3
579 (33.5%)
Phase 1
478 (27.7%)
Phase 2
409 (23.7%)
Phase 4
210 (12.2%)
Not Applicable
51 (3.0%)
Early Phase 1
1 (0.1%)

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Not Applicable
Recruiting
Conditions
Obesity or Overweight
Interventions
Drug: Placebo
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
340
Registration Number
NCT07081958
Locations
🇺🇸

Tristar Clinical Investigations, Philadelphia, Pennsylvania, United States

🇺🇸

Manassas Clinical Research Center, Manassas, Virginia, United States

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Not Applicable
Not yet recruiting
Conditions
Multiple Sclerosis
Interventions
Drug: Ocrelizumab Test Formulation
Drug: Ocrelizumab Reference Formulation
First Posted Date
2025-07-20
Last Posted Date
2025-07-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
182
Registration Number
NCT07074886

A COPD Data Registry for Participants With Frequent Exacerbations

Not yet recruiting
Conditions
COPD
First Posted Date
2025-07-10
Last Posted Date
2025-07-25
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
3000
Registration Number
NCT07059273

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Not Applicable
Not yet recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
60
Registration Number
NCT07054190

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

Phase 4
Recruiting
Conditions
Dry Eye Disease
Interventions
Drug: Vevye®
Drug: Xiidra®
First Posted Date
2025-06-18
Last Posted Date
2025-07-25
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
350
Registration Number
NCT07025811
Locations
🇺🇸

Eye Research Foundation, Newport Beach, California, United States

🇺🇸

Piedmont Eye Center, Lynchburg, Virginia, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 406
  • Next

News

HER2-Positive Gastric Cancer Pipeline Shows Robust Activity with 20+ Companies Developing Novel Therapies

DelveInsight's 2025 pipeline report reveals over 20 companies actively developing more than 20 innovative therapies for HER2-positive gastric cancer treatment.

Global GVHD Clinical Trials Review Reveals Key Trends and Strategic Opportunities for 2025

A comprehensive analysis of the global Graft Versus Host Disease clinical trial landscape shows significant activity across G7 and E7 countries, offering strategic insights for pharmaceutical companies.

Over 220 Pipeline Therapies in Development for Non-Hodgkin's Lymphoma, Reports DelveInsight

DelveInsight's 2025 pipeline report reveals more than 200 companies developing 220+ therapies for Non-Hodgkin's Lymphoma, demonstrating robust research activity in this therapeutic area.

B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025

DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.

Expert Insights: Navigating the Complex Landscape of Biosimilars and Biobetters Development

Biosimilars must demonstrate close similarity to reference products in quality, non-clinical, and clinical data, while biobetters are purposely differentiated to deliver improvements over originators.

Roche to Challenge Illumina's Dominance with Novel Sequencing Technology Launch in 2024

Roche Holding AG announces plans to introduce innovative sequencing by expansion technology in 2024, potentially disrupting Illumina's long-standing market leadership in next-generation sequencing.

Breakthrough Therapy Designations Driving Pharmaceutical Market to Reach $287.5 Billion by 2029

• The global market for breakthrough therapies is projected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, representing a compound annual growth rate of 13.8%. • Expedited regulatory pathways, including the FDA's Breakthrough Therapy Designation and EMA's PRIME scheme, are accelerating development of innovative treatments for serious conditions like cancer and cardiovascular disease. • Recent success stories include AbbVie's epcoritamab for follicular lymphoma and Merck's sotatercept-csrk (WINREVAIR) for pulmonary arterial hypertension, both receiving breakthrough designations.

Lupus Nephritis Clinical Trial Landscape Shows Active Development

• The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies. • Key players like AstraZeneca, Roche, and Novartis are advancing drugs such as Anifrolumab and Ianalumab through clinical trials. • Recent trial activities include Adicet Bio dosing the first patient in a Phase I trial of ADI-001 and Kyverna presenting updated clinical data on KYV-101. • Various therapeutic modalities, including monoclonal antibodies and cell therapies, are being explored across different clinical stages.

Global Biotechnology Market Projected to Reach USD 3.54 Trillion by 2033, Driven by Therapeutic Innovations

The global biotechnology market is expected to grow from USD 1.68 trillion in 2024 to USD 3.54 trillion by 2033, representing a CAGR of 9.18%, according to Cervicorn Consulting.

Weight Loss Market Booms as Pharma Responds to Obesity Crisis

The weight loss drugs market is projected to grow at an annual rate of 43.73% through 2032, driven by rising obesity rates and increased employer coverage.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.